Abstract
Stress and anxiety disorders are risk factors for depression and these behaviors are modulated by corticotrophin-releasing factor receptor 1 (CRFR1) and serotonin receptor (5-HT2R). However, the potential behavioral and cellular interaction between these two receptors is unclear. We found that pre-administration of corticotrophin-releasing factor (CRF) into the prefrontal cortex of mice enhanced 5-HT2R–mediated anxiety behaviors in response to 2,5-dimethoxy-4-iodoamphetamine. In both heterologous cell cultures and mouse cortical neurons, activation of CRFR1 also enhanced 5-HT2 receptor–mediated inositol phosphate formation. CRFR1-mediated increases in 5-HT2R signaling were dependent on receptor internalization and receptor recycling via rapid recycling endosomes, resulting in increased expression of 5-HT2R on the cell surface. Sensitization of 5-HT2R signaling by CRFR1 required intact PDZ domain–binding motifs at the end of the C-terminal tails of both receptor types. These data suggest a mechanism by which CRF, a peptide known to be released by stress, enhances anxiety-related behavior via sensitization of 5-HT2R signaling.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Anisman, H., Merali, Z. & Stead, J.D.H. Experimental and genetic contributions to depressive- and anxiety-like disorders: clinical and experimental studies. Neurosci. Biobehav. Rev. 32, 1185–1206 (2008).
Millan, M.J. Serotonin 5–HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 60, 441–460 (2005).
Holsboer, F. Corticotropin-releasing hormone modulators and depression. Curr. Opin. Investig. Drugs 4, 46–50 (2003).
Nestler, E.J. et al. Neurobiology of depression. Neuron 34, 13–25 (2002).
Leonard, B.E. The HPA and immune axes in stress: the involvement of the serotonergic system. Eur. Psychiatry 20, S302–S306 (2005).
Holmes, A., Heilig, M., Rupniak, N.M., Steckler, T. & Griebel, G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol. Sci. 24, 580–588 (2003).
Davis, M. The role of the amygdala in fear and anxiety. Annu. Rev. Neurosci. 15, 353–375 (1992).
Merali, Z., Khan, S., Michaud, D.S., Shippy, S.A. & Anisman, H. Does amygdaloid corticotropin-releasing hormone (CRF) mediate anxiety-like behaviors? Dissociation of anxiogenic effects and CRF release. Eur. J. Neurosci. 20, 229–239 (2004).
Müller, M.B. et al. Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat. Neurosci. 6, 1100–1107 (2003).
Millan, M.J., Marin, P., Bockaert, J. & la Cour, C.M. Signaling at G protein–coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol. Sci. 29, 454–464 (2008).
Bockaert, J., Claeysen, S., Bécamel, C., Dumuis, A. & Marin, P. Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling and roles in synaptic modulation. Cell Tissue Res. 326, 553–572 (2006).
Heisler, L.K., Zhou, L., Bajwa, P., Hsu, J. & Tecott, L.H. Serotonin 5-HT(2C) receptors regulate anxiety-like behavior. Genes Brain Behav. 6, 491–496 (2007).
Weisstaub, N.V. et al. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science 313, 536–540 (2006).
Valdez, G.R. Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date. CNS Drugs 20, 887–896 (2006).
Celada, P., Puig, M., Amargós-Bosch, M., Adell, A. & Artigas, F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J. Psychiatry Neurosci. 29, 252–265 (2004).
Pillay, N.S. & Stein, D.J. Emerging anxiolytics. Expert Opin. Emerg. Drugs 12, 541–554 (2007).
Merali, Z. et al. Bombesin receptors as novel anti-anxiety therapeutic target; non-peptide antagonist PD 176252 reduces anxiety and 5-HT release through BB1 receptor. J. Neurosci. 26, 10387–10396 (2006).
Trimble, N., Johnson, A.C., Foster, A. & Greenwood-van Meerveld, B. Corticotropin-releasing factor receptor 1-deficient mice show decreased anxiety and colonic sensitivity. Neurogastroenterol. Motil. 19, 754–760 (2007).
Vale, W., Spiess, J., Rivier, C. & Rivier, J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213, 1394–1397 (1981).
Owens, M.J. & Nemeroff, C.B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev. 43, 425–473 (1991).
Chen, R., Lewis, K.A., Perrin, M.H. & Vale, W.W. Expression cloning of a human corticotropin releasing–factor receptor. Proc. Natl. Acad. Sci. USA 90, 8967–8971 (1993).
Lovenberg, T.W. et al. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc. Natl. Acad. Sci. USA 92, 836–840 (1995).
Cummings, S., Elde, R., Ells, J. & Lindall, A. Corticotropin-releasing factor immunoreactivity is widely distributed within the central nervous system of the rat. J. Neurosci. 3, 1355–1368 (1983).
Chalmers, D.T., Lovenberg, T.W. & De Souza, E.B. Localization of novel corticotropin- releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J. Neurosci. 15, 6340–6350 (1995).
De Souza, E.B. et al. Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: an autoradiographic study. J. Neurosci. 5, 3189–3203 (1985).
Hoyer, D. et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev. 46, 157–203 (1994).
Tan, H., Zhong, P. & Yan, Z. Corticotropin-releasing factor and acute stress prolongs serotonergic regulation of GABA transmission in prefrontal cortical pyramidal neurons. J. Neurosci. 24, 5000–5008 (2004).
Bhatnagar, A. et al. The dynamin-dependent, arrestin-independent internalization of 5-hydroxytryptamine 2A (5-HT2A) serotonin receptors reveals differential sorting of arrestins and 5-HT2A receptors during endocytosis. J. Biol. Chem. 276, 8269–8277 (2001).
Holmes, K.D., Babwah, A.V., Dale, L.B., Poulter, M.O. & Ferguson, S.S.G. Differential regulation of corticotropin releasing factor receptor 1α endocytosis and trafficking by β-arrestins and Rab GTPases. J. Neurochem. 96, 934–949 (2006).
Xia, Z., Gray, J.A., Compton-Toth, B.A. & Roth, B.L. A direct interaction of PSD-95 with 5-HT2A serotonin receptors regulates receptor trafficking and signal transduction. J. Biol. Chem. 278, 21901–21908 (2003).
Bécamel, C. et al. Synaptic multinositol phosphaterotein complexes associated with 5-HT2C receptors: a proteomic approach. EMBO J. 21, 2332–2342 (2002).
Bécamel, C. et al. The serotonin 5-HT2A and 5-HT2C receptors interact with specific sets of PDZ proteins. J. Biol. Chem. 279, 20257–20266 (2004).
Gavarini, S. et al. Opposite effects of PSD-95 and MPP3 PDZ proteins on serotonin 5-hydroxytryptamine2C receptor desensitization and membrane stability. Mol. Biol. Cell 17, 4619–4631 (2006).
Abbas, A.I. et al. PSD-95 is essential for hallucinogen and atypical antinositol phosphatesychotic drug actions at serotonin receptors. J. Neurosci. 29, 7124–7136 (2009).
Anisman, H., Merali, Z. & Hayley, S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity of depression with neurodegenerative disorders. Prog. Neurobiol. 85, 1–74 (2008).
Xia, Z., Hufeisen, S.J., Gray, J.A. & Roth, B.L. The PDZ-binding domain is essential for the dendritic targeting of 5-HT2A serotonin receptors in cortical pyramidal neurons in vitro. Neuroscience 122, 907–920 (2003).
Doherty, M.D. & Pickel, V.M. Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area. Brain Res. 864, 176–185 (2000).
Gray, J.A. et al. Cell type–specific effects of endocytosis inhibitors on 5-hydroxytryptamine (2A) receptor desensitization and resensitization reveal an arrestin-, GRK2- and GRK5-independent mode of regulation in human embryonic kidney 293 cells. Mol. Pharmacol. 60, 1020–1030 (2001).
Schlag, B.D., Lou, Z., Fennell, M. & Dunlop, J. Ligand dependency of 5-hydroxytryptamine2C receptor internalization. J. Pharmacol. Exp. Ther. 310, 865–870 (2004).
Marion, S., Weiner, D.M. & Caron, M.G. RNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2c receptor isoforms. J. Biol. Chem. 279, 2945–2954 (2004).
Collingridge, G.L., Isaac, J.T. & Wang, Y.T. Receptor trafficking and synaptic plasticity. Nat. Rev. Neurosci. 5, 952–962 (2004).
Hu, L.A. et al. β1-adrenergic receptor association with PSD-95. Inhibition of receptor internalization and facilitation of β1-adrenergic receptor interaction with N-methyl-D-aspartate receptors. J. Biol. Chem. 275, 38659–38666 (2000).
Ferguson, S.S.G. Evolving concepts in G protein–coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev. 53, 1–24 (2001).
Seachrist, J.L., Anborgh, P.H. & Ferguson, S.S.G. β2-adrenergic receptor internalization, endosomal sorting and plasma membrane recycling are regulated by Rab GTPases. J. Biol. Chem. 275, 27221–27228 (2000).
Ferguson, S.S.G. & Caron, M.G. Green fluorescent protein tagged β-arrestin translocation as a measure of G protein–coupled receptor activation. Methods Mol. Biol. 237, 121–126 (2004).
Dhami, G.K. et al. Protein-coupled receptor kinase 2 RGS homology domain binds to both metabotropic glutamate receptor 1a and Gαq to attenuate signaling. J. Biol. Chem. 279, 16614–16620 (2004).
Conn, P.J. & Sanders-Bush, E. Serotonin-stimulated phosphoinositide turnover: mediation by the S2 binding site in rat cerebral cortex, but not in subcortical regions. J. Pharmacol. Exp. Ther. 234, 195–203 (1985).
Franklin, K.B.J. & Paxinos, G. The Mouse Brain in Stereotaxic Coordinates (Academic Press, San Diego, 1997).
Acknowledgements
A.C.M. and D.L. received Canadian Institutes for Health Research (CIHR) fellowships. K.D.H. received a fellowship from the Ontario Mental Health Foundation. L.C.-A. was supported by a Conventions Industrielles de Formation par la Recherche fellowship from CisBio and the French government. J.-P.P. was supported by CNRS, INSERM, the Agence Nationale de la Recherche grant Blan06-3_135092 and CisBio. S.S.G.F. and H.A. hold Tier I Canada Research Chairs, and S.S.G.F. is a Heart and Stroke Foundation of Ontario Career Investigator. This research was funded by CIHR grant MOP 62738 to S.S.G.F., CIHR grant MOP 81118 to H.A., US National Institutes of Health grants R01MH61887 and U19MH82441 and the Michael Hooker Distinguished Chair of Pharmacology to B.L.R.
Author information
Authors and Affiliations
Contributions
M.O.P., K.D.H., A.C.M., H.A. and S.S.G.F. conceived the experiments. H.A. carried out the behavioral experiments. A.C.M., K.D.H., L.B.D., L.C.-A., J.-P.P., L.D., P.N.Y. and D.L. performed the rest of the experiments. S.S.G.F., A.C.M., B.L.R. and H.A. analyzed the data and wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–5 and Table 1 (PDF 580 kb)
Rights and permissions
About this article
Cite this article
Magalhaes, A., Holmes, K., Dale, L. et al. CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nat Neurosci 13, 622–629 (2010). https://doi.org/10.1038/nn.2529
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nn.2529
This article is cited by
-
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders
Signal Transduction and Targeted Therapy (2023)
-
Multisite regulation integrates multimodal context in sensory circuits to control persistent behavioral states in C. elegans
Nature Communications (2023)
-
Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics
Molecular Psychiatry (2023)
-
Sex differences in offspring risk and resilience following 11β-hydroxylase antagonism in a rodent model of maternal immune activation
Neuropsychopharmacology (2023)
-
Moderate prenatal alcohol exposure modifies sex-specific CRFR1 activity in the central amygdala and anxiety-like behavior in adolescent offspring
Neuropsychopharmacology (2022)